Response assessment
Tumors
TUMORS, DISEASE PROGRESSION, DISEASE PROGRESSION
Response and progression were evaluated using a modified version of the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) (mRECIST). Disease progression for this protocol was defined as meeting the RECIST for disease progression on two consecutive evaluations at least 6 weeks apart. Patients were evaluated every 6 weeks until disease progression was confirmed on two subsequent scans.